acetazolamide and Aging studies

Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)

Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.

Research Excerpts

Excerpt	Relevance	Reference
"Acetazolamide (ACM) treatment partially reversed the growth deficit of kl/kl mice."	5.43	Acetazolamide sensitive tissue calcification and aging of klotho-hypomorphic mice. ( Alesutan, I; Castor, T; Kohlhofer, U; Kübler, L; Kuro-o, M; Lang, F; Leibrock, CB; Mannheim, JG; Michael, D; Pichler, BJ; Quintanilla-Martinez, L; Rosenblatt, KP; Voelkl, J, 2016)
"Treatment with acetazolamide, at a dosage of 0."	5.28	[Serous retinal detachment. Value of acetazolamide]. ( Gonzalez, C, 1992)
" From a review of the literature, the optimal technique employs quantitative 15O-water PET imaging determinations of cerebral blood flow (CBF) and acetazolamide (ACZ) (1 g iv with measurements at 10- to 20-min post-administration) as the vasodilating agent."	3.72	Technical issues in the determination of cerebrovascular reserve in elderly subjects using 15O-water PET imaging. ( Boles Ponto, LL; Hichwa, RD; Leonard Watkins, G; Schultz, SK, 2004)
"In aging eyes phenylephrine drops have no significant effect on the depth of the anterior chamber, whereas pilocarpine drops produce a significant shallowing."	3.66	Acute shallowing of the anterior chamber. ( Mapstone, R, 1981)
"Acetazolamide (ACM) treatment partially reversed the growth deficit of kl/kl mice."	1.43	Acetazolamide sensitive tissue calcification and aging of klotho-hypomorphic mice. ( Alesutan, I; Castor, T; Kohlhofer, U; Kübler, L; Kuro-o, M; Lang, F; Leibrock, CB; Mannheim, JG; Michael, D; Pichler, BJ; Quintanilla-Martinez, L; Rosenblatt, KP; Voelkl, J, 2016)
"The effects of cerebral amyloid angiopathy (CAA) on the function of cerebral blood vessels were analyzed applying cerebral blood volume (CBV)-based fMRI to transgenic arcA beta mice."	1.36	Vascular response to acetazolamide decreases as a function of age in the arcA beta mouse model of cerebral amyloidosis. ( Knobloch, M; Mueggler, T; Nitsch, RM; Princz-Kranz, FL; Rudin, M, 2010)
"Treatment with acetazolamide, at a dosage of 0."	1.28	[Serous retinal detachment. Value of acetazolamide]. ( Gonzalez, C, 1992)
"Acetazolamide inhibition was utilized to distinguish between activities of the acetazolamide-sensitive (CA I and II) and acetazolamide-resistant (CA III) forms of the enzyme."	1.26	Carbonic anhydrase activity in skeletal muscle fiber types, axons, spindles, and capillaries of rat soleus and extensor digitorum longus muscles. ( Bain, J; Ellis, S; Riley, DA, 1982)

Research

Studies (27)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Adherence

Timeframe	Studies, this research(%)	All Research%
pre-1990	13 (48.15)	18.7374
1990's	8 (29.63)	18.2507
2000's	4 (14.81)	29.6817
2010's	2 (7.41)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Leibrock, CB	1
Alesutan, I	1
Voelkl, J	1
Michael, D	1
Castor, T	1
Kohlhofer, U	1
Quintanilla-Martinez, L	1
Kübler, L	1
Mannheim, JG	1
Pichler, BJ	1
Rosenblatt, KP	1
Kuro-o, M	1
Lang, F	1
Princz-Kranz, FL	1
Mueggler, T	1
Knobloch, M	1
Nitsch, RM	1
Rudin, M	1
ARMALY, MF	2
HALASA, AH	1
Settakis, G	1
Molnár, C	1
Kerényi, L	1
Kollár, J	1
Legemate, D	1
Csiba, L	1
Fülesdi, B	1
Boles Ponto, LL	1
Schultz, SK	1
Leonard Watkins, G	1
Hichwa, RD	1
Hewitt, A	1
Barrie, R	1
Graham, M	1
Bogus, K	1
Leiter, JC	1
Erlichman, JS	1
Woodbury, DM	1
Riley, DA	1
Ellis, S	1
Bain, J	1
Mapstone, R	1
Guilleminault, C	1
Silvestri, R	1
Mondini, S	1
Coburn, S	1
Hannhart, B	1
Bairam, A	1
Marchal, F	1
Preston, JE	1
Dyas, M	1
Johanson, CE	2
Centofanti, M	1
Manni, GL	1
Napoli, D	1
Bucci, MG	1
Shah, M	1
Quigley, R	1
Baum, M	1
Bar, A	1
Vax, E	1
Striem, S	1
Marstrand, JR	1
Garde, E	1
Rostrup, E	1
Ring, P	1
Rosenbaum, S	1
Mortensen, EL	1
Larsson, HB	1
Cammer, W	1
Holmes, RS	1
Kupfer, C	1
Gaasterland, D	1
Ross, K	1
Gonzalez, C	1
Parandoosh, Z	1
Dyas, ML	1
Brion, LP	1
Zavilowitz, BJ	1
Rosen, O	1
Schwartz, GJ	1
Sullivan, HG	1
Kingsbury, TB	1
Morgan, ME	1
Jeffcoat, RD	1
Allison, JD	1
Goode, JJ	1
McDonnell, DE	1
Skipski, IA	1
Scott, WN	1
Petty, WC	1
Karler, R	1
Lindeman, RD	1
Lee, TD	1
Yiengst, MJ	1
Shock, NW	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Effect of Inhaled Corticosteroids on Intraocular Pressure in Patients With Ocular Hypertension or Controlled Glaucoma.[NCT02338362]	Phase 4	22 participants (Actual)	Interventional	2014-09-30	Completed
C-arm Cone Beam CTA and CTP With Acetazolamide Challenge in Aneurysmal Subarachnoid Hemorrhage: Evaluating Predictability for Early Ischemia in Cerebral Vasospasm[NCT03377049]	Phase 4	11 participants (Actual)	Interventional	2019-07-28	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Adherence was calculated from self-reported study diaries and correlated to a counter that measured number of inhaled puffs built into the placebo metered-dose inhalers (NCT02338362)
Timeframe: Completion of study, up to 6 weeks

Mean Intraocular Pressure

Intervention	percentage of required doses (Mean)
Fluticasone	93.6
Saline Placebo	96.1

Masked assessment of intraocular pressure using goldmann application tonometry. Mean of 2 measurements within 1 mmHg will be recorded. (NCT02338362)
Timeframe: week 6

Mean Visual Acuity

Intervention	mmHg (Mean)
Fluticasone	14.7
Saline Placebo	14.8

best corrected logMAR visual acuity for each eye. 20/20 vision corresponds with a logMAR score of 0, while negative logMAR scores indicate better than 20/20 vision, values > 0.5 correspond with low vision, and values > 1.3 correspond with blindness. (NCT02338362)
Timeframe: week 6

Intraocular Pressure Elevation >20% From Baseline

Intervention	logMAR (Mean)
Fluticasone	0.15
Saline Placebo	0.15

Participants with 2 consecutive intraocular pressure measurements exceeding 20% increase from baseline were discontinued from study. (NCT02338362)
Timeframe: within 6-week observation period

Side Effects

Intervention	participants (Number)
	elevation >20%	no elevation >20%
Fluticasone	1	9
Saline Placebo	0	10

subjective (reported) and objective (slit lamp examination) side-effects attributable to study medications (NCT02338362)
Timeframe: from baseline to week 6

Number of Participants Who Develop Delayed Cerebral Vasospasm

Intervention	participants (Number)
	lens opacity	throat discomfort	headache	difficulty sleeping	no adverse effects
Fluticasone	0	1	1	0	8
Saline Placebo	0	1	0	1	8

Clinical neurological deterioration not attributable to other causes, mores specifically not due to re-bleeding, hydrocephalus, or metabolic changes. (NCT03377049)
Timeframe: Day 1-14 during the hospitalization

Percent Change in Left Hemisphere Brain Imaging Maps

Intervention	Participants (Count of Participants)
Acetazolamide Challenge	2

Using perfusion map values, relative percent change will be calculated (NCT03377049)
Timeframe: pre and post perfusion during imaging procedure, up to an hour

Percent Change in Right Hemisphere Brain Imaging Maps

Intervention	percent change (Mean)
Acetazolamide Challenge	19.785